Medtronic on go to launch study of extended-use insulin infusion set

The FDA has signed off on a pivotal study evaluating Medtronic’s (MDT+0.5%) extended-wear insulin infusion set that will allow use for up to seven days (current infusion sets must be changed every two-to-three days).

The non-randomized single-arm trial will enroll up to 150 adult type 1 diabetics who are currently using the MiniMed 670G system.

The company says the longer use will enable the coordination of changing the infusion set and sensor at the same time.

https://seekingalpha.com/news/3492592-medtronic-go-launch-study-extended-use-insulin-infusion-set